| Year |
Citation |
Score |
| 2020 |
Scotto L, Kinahan C, Casadei B, Mangone M, Douglass E, Vundavalli MV, Marchi E, Ma H, George C, Montanari F, Califano A, O'Connor OA. Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers. Genes, Chromosomes & Cancer. PMID 32614991 DOI: 10.1002/Gcc.22884 |
0.382 |
|
| 2020 |
Kinahan C, Mangone MA, Scotto L, Visentin M, Marchi E, Cho HJ, O'Connor OA. The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma. Oncotarget. 11: 1576-1589. PMID 32405334 DOI: 10.18632/oncotarget.27516 |
0.555 |
|
| 2016 |
Deng C, Lipstein MR, Scotto L, Jirau Serrano XO, Mangone MA, Li S, Vendome J, Hao Y, Xu X, Deng SX, Realubit RB, Tatonetti NP, Karan C, Lentzsch S, Fruman DA, et al. Silencing c-Myc translation as a therapeutic strategy through targeting PI3K delta and CK1 epsilon in hematological malignancies. Blood. PMID 27784673 DOI: 10.1182/Blood-2016-08-731240 |
0.327 |
|
| 2016 |
Deng C, Lipstein M, Scotto L, Serrano XOJ, Mangone M, Li S, Vendome J, Hao Y, Xu X, Liu X, Pal I, Deng S, Tatonetti NP, Lentzsch S, Honig B, et al. Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies Blood. 128: 291-291. DOI: 10.1182/Blood.V128.22.291.291 |
0.461 |
|
| 2015 |
Zullo KM, Guo Y, Cooke LS, Jirau-Serrano X, Mangone M, Scotto L, Amengual JE, Mao Y, Nandakumar R, Cremers S, Duong J, Mahadevan D, O'Connor OA. Aurora A Kinase Inhibition Selectively Synergizes With Histone Deactylase Inhibitor Through Cytokinesis Failure In T-Cell Lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25878331 DOI: 10.1158/1078-0432.Ccr-15-0033 |
0.385 |
|
| 2015 |
Deng C, Lipstein M, Scotto L, Hao Y, Tatonetti NP, Mangone M, Li S, Lentzsch S, Realubit RB, Karan C, O'Connor OA. Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas Blood. 126: 593-593. DOI: 10.1182/Blood.V126.23.593.593 |
0.46 |
|
| 2015 |
Kalac M, Mangone M, Rinderspacher A, Deng S, Scotto L, Vendome J, Bansal M, Califano A, Landry D, O'Connor OA. Targeting NF-κB with First in Class N-Quinoline Benzenesulfonamides (NQBS) Reveals Potent Activity in Models of Diffuse Large B-Cell Lymphoma (DLBCL) Blood. 126: 4435-4435. DOI: 10.1182/Blood.V126.23.4435.4435 |
0.366 |
|
| 2015 |
Scotto L, Jirau-Serrano X, Zullo K, Mangone M, Amengual JE, Deng C, O'Connor OA. The ATM Inhibitor KU60019 Synergizes the Antineoplastic Effect of Romidepsin in Mantle Cell Lymphoma (MCL) Blood. 126: 3703-3703. DOI: 10.1182/Blood.V126.23.3703.3703 |
0.511 |
|
| 2014 |
Zullo K, Guo Y, Cooke L, Serrano XJ, Mangone M, Scotto L, Amengual JE, Mahadevan D, O'Connor OA. The Investigational Aurora A Kinase Inhibitor Alisertib Exhibits Broad Activity in Preclinical Models of T-Cell Lymphoma and Is Highly Synergistic with Romidepsin Blood. 124: 4493-4493. DOI: 10.1182/Blood.V124.21.4493.4493 |
0.465 |
|
| 2014 |
Deng C, Lipstein M, Serrano XJ, Mangone M, Scotto L, O'Connor OA, Sportelli P, Miskin HP, Viswanadha S. Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-Kappab in Models of B- and T-Cell Lymphoma Blood. 124: 1770-1770. DOI: 10.1182/Blood.V124.21.1770.1770 |
0.488 |
|
| 2011 |
Mangone M, Scotto L, Marchi E, O'Connor OA, Cho HJ. Pralatrexate Has Potent Activity Against Multiple Myeloma In Vitro and In Vivo , and Activity Correlates with Tumor RFC-1 and DHFR Expression Blood. 118: 1831-1831. DOI: 10.1182/Blood.V118.21.1831.1831 |
0.635 |
|
| 2011 |
Nardiello T, Mei A, Mangone M, Cho HJ. CT7 (MAGE-C1) Promotes Survival and Interacts with STAT1 and PIASy in Multiple Myeloma Cells Blood. 118: 1807-1807. DOI: 10.1182/Blood.V118.21.1807.1807 |
0.39 |
|
| 2011 |
Mangone M, Marchi E, Scotto L, O'Connor OA, Cho HJ. Abstract 4530: Pralatrexate-induced apoptosis in multiple myeloma cells correlates with RFC-1 and DHFR expression Cancer Research. 71: 4530-4530. DOI: 10.1158/1538-7445.Am2011-4530 |
0.647 |
|
| 2010 |
Lendvai N, Gnjatic S, Ritter E, Mangone M, Austin W, Reyner K, Jayabalan D, Niesvizky R, Jagannath S, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ. Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immunity. 10: 4. PMID 20108890 |
0.598 |
|
| Show low-probability matches. |